| Company Name: | Advanced Life Sciences Holdings, Inc. | | Ticker Symbol: | ADLS | | | WWW Address: | www.advancedlifesciences.com |
| CEO: | Michael T. Flavin,PhD | | No. of Employees: | 16 |
| Common Issue Type: | CS | | Business Description: | Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, oncology and respiratory disease.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.42 |  0.0 | - | - | | 0.05 | 0.05 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 4.5 | 10.8 | 2.47 | -1.80 | 0.00 | 0.0 | 0.0 | 0.06 - 0.03 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.05 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 4.5 | mil |
| Latest Shares Outstanding | 10.8 | mil |
| Earnings pS (EPS) | -1.80 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 47,053 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 8.8 | mil |
| Float as % of Shares Outstanding | 81.3 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 580.60 | % |
| Research & Devlopment (R&D) as % of Revenue | 332.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.2 | % |
| Return on Assets (ROA) | -1206.6 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 96.0 | % |
| Current Ratio | 0.0 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | -0.95 | $ |
| Cash pS | 0.01 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.90 | $ |
| Cash Flow pS | -0.88 | $ |
| Free Cash Flow pS | -0.60 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -0.06 | |
| Price/Cash Flow | -0.1 | |
| Price/Free Cash Flow | -0.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 98 | | |
| 4 Weeks | 0.05 | 0.05 | 0.05 | 0.0 | 106 | | |
| 13 Weeks | 0.05 | 0.05 | 0.05 | 0.0 | 104 | | |
| 26 Weeks | 0.05 | 0.05 | 0.05 | 0.0 | 88 | | |
| 52 Weeks | 0.06 | 0.03 | 0.05 | 0.0 | 101 | 18 | 4,593 |
| YTD | 0.05 | 0.05 | - | 0.0 | 95 | | |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 2.47 | 2.24 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | -14.91 | NA | -56.19 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -73.0 | -100.0 | -73.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | -100.0 | 0.0 |
| EPS $ | 3.00 | -5.70 | 3.00 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -1,329.78 |
| Current Ratio | 0.0 |
| Quick Ratio (Acid Test) | 0.0 |
| Liquidity Ratio (Cash) | 0.02 |
| Receivables Turnover | 2.8 |
| Average Collection Period | 129 |
| Working Capital/Equity | 105.7 |
| Working Capital pS | -1.19 |
| Cash-Flow pS | -1.09 |
| Free Cash-Flow pS | -0.74 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -67.91 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 1358.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | -0.2 |
| LT Debt/Total Liabilities | 0.2 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | -9.75 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 67.92 |
| Tobin's Q Ratio | 0.70 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.79 |
| Enterprise Value (EV)/Free Cash Flow | -0.18 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -0.06 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -0.1 |
| Price/Free Cash Flow Ratio - LTM | -0.1 |
| Price/Sales Ratio | 0.72 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.21 |
| Tangible Book Value pS - LTM | -0.90 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | -0.90 |
| Cash pS - LTM | 0.01 |
| Cash Flow pS - LTM | -0.88 |
| Free Cash Flow pS - LTM | -0.60 |
| Earnings pS (EPS) | -1.80 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -854.29 |
| Free Cash Flow Margin 5YEAR AVG | -13,107.46 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.08 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -0.08 |
| Return on Capital Invested (ROCI) | 96.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -283.9 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | -1206.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | -155.8 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | |
| Revenue per Employee | 47,053 |
| Net Income per Employee | -582,625 |
| Average Collection Period | |
| Receivables Turnover | 2.8 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 227.28 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | -0.07 |
| Fixed Assets Turnover | 1.33 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 4.72 |
| Revenue per $ Plant | 16.90 |
| Revenue per $ Common Equity | -0.08 |
| Revenue per $ Capital Invested | -0.08 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 580.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 786.8 |
| Research & Devlopment (R&D) as % of Revenue | 332.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 332.0 |
|
|  
|
| |
 |  |
